Show simple item record

A phase II study of sulofenur (LY186641) in gastric cancer.

dc.contributor.authorKamthan, A
dc.contributor.authorScarffe, J Howard
dc.contributor.authorWalling, J
dc.contributor.authorHatty, S
dc.contributor.authorPeters, B
dc.contributor.authorColeman, R
dc.contributor.authorSmyth, J F
dc.date.accessioned2010-08-11T17:19:28Z
dc.date.available2010-08-11T17:19:28Z
dc.date.issued1992-08
dc.identifier.citationA phase II study of sulofenur (LY186641) in gastric cancer. 1992, 3 (4):331-5 Anticancer Drugsen
dc.identifier.issn0959-4973
dc.identifier.pmid1421428
dc.identifier.urihttp://hdl.handle.net/10541/109508
dc.description.abstractSulofenur is a novel diarylsulfonylurea with proven anti-tumor activity in murine tumor models. In this phase II study in patients with advanced gastric or gastroesophageal adenocarcinoma, 17 patients were treated with sulofenur orally at 700 mg/m2 for 14 days every 3 weeks. No tumor responses were seen. The main toxicities were anemia, methemoglobinemia and abnormalities in liver function tests. These toxicities precluded dose escalation. However, plasma levels of sulofenur, and its hydroxy and keto metabolites were probably insufficient to exert anti-tumor effect in comparison with data from murine studies. Further structure-activity studies are warranted.
dc.language.isoenen
dc.subjectAnticancerous Agentsen
dc.subjectOesophageal Canceren
dc.subjectStomach Canceren
dc.subject.meshAdenocarcinoma
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAntineoplastic Agents
dc.subject.meshEsophageal Neoplasms
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshStomach Neoplasms
dc.subject.meshSulfonylurea Compounds
dc.titleA phase II study of sulofenur (LY186641) in gastric cancer.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Christie Hospital, Manchester, UK.en
dc.identifier.journalAnticancer Drugsen
html.description.abstractSulofenur is a novel diarylsulfonylurea with proven anti-tumor activity in murine tumor models. In this phase II study in patients with advanced gastric or gastroesophageal adenocarcinoma, 17 patients were treated with sulofenur orally at 700 mg/m2 for 14 days every 3 weeks. No tumor responses were seen. The main toxicities were anemia, methemoglobinemia and abnormalities in liver function tests. These toxicities precluded dose escalation. However, plasma levels of sulofenur, and its hydroxy and keto metabolites were probably insufficient to exert anti-tumor effect in comparison with data from murine studies. Further structure-activity studies are warranted.


This item appears in the following Collection(s)

Show simple item record